Key result
Diabetic MAFLD had higher rates of high 10-year cardiovascular risk and moderate-to-high fibrosis risk than other MAFLD subtypes.
Why the study?
Do different MAFLD subtypes (diabetic, metabolic dysfunction, and overweight MAFLD) differ in sociodemographic characteristics, advanced liver fibrosis risk, and 10-year predicted cardiovascular risk among adults in Malaysia?
Cross-Sectional (n=309)
Yes
Do different MAFLD subtypes (diabetic, metabolic dysfunction, and overweight MAFLD) differ in sociodemographic characteristics, advanced liver fibrosis risk, and 10-year predicted cardiovascular risk among adults in Malaysia?
Answers are grounded in this paper and cite their sources.
Subtyping MAFLD in Malaysian adults identifies the diabetic MAFLD phenotype as carrying a markedly higher burden of predicted 10-year cardiovascular risk (57.6%) and advanced liver fibrosis risk (22.7%), supporting targeted risk stratification and cardiometabolic management.
We aimed to describe the sociodemographic and clinical characteristics of subtypes of metabolic dysfunction-associated fatty liver disease (MAFLD) in Malaysia. Adults with MAFLD were identified from a 2023 nationwide community-based cross-sectional study. Three mutually exclusive MAFLD subtypes were classified first by diabetes status (diabetic MAFLD), then by ≥ 2 metabolic dysfunctions (metabolic dysfunction MAFLD), and finally by overweight/obesity with < 2 metabolic dysfunctions (overweight MAFLD). Among 309 respondents with MAFLD, the mean age was 46.8 ± 14.8 years, with a balanced sex distribution, and most were Malay (63.8%) and married or living with a partner (71.8%). The diabetic MAFLD subtype was characterised by older age, Indian ethnicity, and a higher proportion of divorced or widowed individuals, whereas younger adults were predominantly represented in the metabolic dysfunction subtype. Metabolic syndrome, hypertension, and raised total cholesterol were more common in the metabolic dysfunction subtype. The diabetic subtype had the highest waist circumference, blood pressure, triglycerides, glycosylated haemoglobin A1c, and fasting blood glucose. A higher proportion (22.7%) of the diabetic subtype had moderate or high risks of advanced liver fibrosis, compared to metabolic dysfunction (8.8%) and overweight (0.0%) subtypes, P = 0.002. Around 57.6% of the diabetic MAFLD subtype had a high 10-year cardiovascular risk compared to 25.8% and 10.0% in the metabolic dysfunction and overweight subtypes, respectively, P < 0.001. Individuals with diabetes, metabolic dysfunction, and overweight MAFLD subtypes in Malaysia had different sociodemographic characteristics and clinical profiles. MAFLD subtypes may be used for risk stratification, and individualised treatment may be considered for different subtypes.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2026) conducted a cross-sectional in Metabolic dysfunction-associated fatty liver disease (MAFLD) (n=309). Diabetic MAFLD subtype vs. Metabolic dysfunction MAFLD and overweight MAFLD subtypes was evaluated on High 10-year cardiovascular risk (>20% Framingham General Cardiovascular Risk Score) (p=< 0.001). Diabetic MAFLD had higher rates of high 10-year cardiovascular risk and moderate-to-high fibrosis risk than other MAFLD subtypes.
Synapse has enriched 10 related papers. Consider them for comparative context: